查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1773201

動物用醫藥品調劑的全球市場的評估:各產品，各給藥途徑，各劑型，各地區，機會，預測(2018年～2032年)

Animal Drug Compounding Market Assessment, By Product, By Animal Type, By Route of Administration, By Dosage Form, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Markets & Data | 英文 245 Pages | 商品交期: 3-5個工作天內

價格

全球獸藥複合市場規模預計將從2024年的19.8億美元增至2032年的36.4億美元，在2025-2032年的預測期內，複合年增長率為7.88%。由於對複合藥物的需求不斷增長，例如將藥片製成調味液體、根據不同物種和大小調整劑量以及製作外用凝膠和咀嚼片，該市場呈現快速增長。

隨著獸醫保健提供者和寵物主人尋求滿足其動物個人化需求的定製藥物，獸藥複合市場正穩步受到關注。合格的藥劑師與獸醫合作，透過配製程序配製藥物，從而開發出標準商業產品中沒有的定製劑型、規格和藥物組合。當標準藥物不適用或無法取得，導致動物治療效果不佳時，這個市場就成為不可或缺的解決方案。在伴侶動物和牲畜的獸醫服務中，配製藥物的使用日益增多，這有助於動物服藥，保護其健康，同時獲得更好的治療效果。當寵物對標準藥物中的非活性成分產生過敏反應、需要根據體重單獨計量劑量或需要調味藥物以改善劑量時，都需要使用此類必需藥物。隨著全球寵物數量的增長，寵物保健支出持續增長，促使對客製化獸藥的需求增加。包括皮膚病學、內分泌學、腫瘤學、神經病學和慢性疼痛管理在內的獸醫治療日益複雜，顯著增加了對個人化治療解決方案的需求。寵物人性化趨勢和全球複合藥房網路的擴張將繼續推動市場成長。

例如，2024年9月，WEDGEWOOD PHARMACY 將複方莫努皮拉韋 (molnupiravir) 引入其處方集，作為貓傳染性腹膜炎 (FIP) 一線和二線治療的新療法。該藥物最初是一種用於人類的複方藥物，經過特殊調味和配製，適用於貓。 WEDGEWOOD PHARMACY 是美國第一家提供貓用莫努皮拉韋配方的獸用複合藥房，該配方包含針對不同FIP類型的多種劑量選擇，包括滲出性、非滲出性、神經性以及眼部感染。配方有調味懸浮液和膠囊劑型。

本報告對全球獸用複方藥市場進行了深入分析，包括市場規模和預測、市場動態以及主要參與者的現狀。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 美國關稅的影響

第4章 摘要整理

第5章 全球動物用醫藥品調劑市場預測(2018年～2032年)

  • 市場規模的分析與預測
    • 金額
  • 市場佔有率的分析與預測
    • 各產品
      • 抗感染劑
      • 抗發炎劑
      • 荷爾蒙，替代品
      • CNS劑
      • 其他
    • 動物類別
      • 寵物
      • 家畜
    • 各給藥途徑
      • 口服
      • 注射
      • 外用
    • 各劑型
      • 懸浮劑
      • 液劑
      • 膠囊
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東·非洲
    • 市場佔有率分析:各企業(前五名公司和其他)(金額)(2024年)
  • 市場地圖分析(2024年)
    • 各產品
    • 動物類別
    • 各給藥途徑
    • 各劑型
    • 各地區

第6章 北美的動物用醫藥品調劑市場預測(2018年～2032年)

  • 市場規模的分析與預測
    • 金額
  • 市場佔有率的分析與預測
      • 各產品
      • 動物類別
      • 各給藥途徑
      • 各劑型
    • 佔有率:各國
      • 美國
      • 加拿大
      • 墨西哥
  • 各國的市場評估
    • 美國的動物用醫藥品調劑市場預測(2018年～2032年)
      • 市場規模的分析與預測
      • 市場佔有率的分析與預測
    • 加拿大
    • 墨西哥

第7章 歐洲的動物用醫藥品調劑市場預測(2018年～2032年)

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 土耳其
  • 波蘭

第8章 亞太地區的動物用醫藥品調劑市場預測(2018年～2032年)

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第9章 南美的動物用醫藥品調劑市場預測(2018年～2032年)

  • 巴西
  • 阿根廷

第10章 中東·非洲的動物用醫藥品調劑市場預測(2018年～2032年)

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第11章 供需的分析

第12章 價值鏈分析

第13章 波特的五力分析

第14章 大環境分析

第15章 價格分析

第16章 市場動態

  • 推動市場要素
  • 市場課題

第17章 市場趨勢與發展

  • 技術概要
  • 近幾年的銷售與核准

第18章 法規結構和革新

第19章 案例研究

第20章 競爭情形

  • 前五名市場領導者公司的競爭矩陣
  • 前五名公司的SWOT分析
  • 前十大主要企業的形勢
    • Partners Group
    • Vimian Group AB
    • Akina Animal Health
    • Davis Islands Pharmacy and Compounding Lab
    • Custom Med Compounding Pharmacy
    • Central Compounding Center South
    • Wellness Pharmacy of Cary
    • Kubat HealthCare
    • Medisca Inc.
    • Chiron Pharmaceuticals Private Limited

第21章 策略性建議

第22章 關於調查公司·免責聲明

Product Code: MX13696

Global animal drug compounding market is projected to witness a CAGR of 7.88% during the forecast period 2025-2032, growing from USD 1.98 billion in 2024 to USD 3.64 billion in 2032. The animal drug compounding market is experiencing rapid growth due to the rising demand for compounded medications, which include converting tablets into flavored liquids, adjusting dosages for different species or sizes, or creating topical gels and chews.

The animal drug compounding market is steadily gaining prominence as veterinary healthcare providers and pet owners seek customized pharmaceutical products that address the individual needs of their animals. Licensed pharmacists, along with veterinarians, prepare medications through compounding procedures, which enable them to develop custom dosage forms, strengths, and drug combinations that standard commercial products do not offer. The market serves as an essential solution for animal care situations where standard medications fail because they are either inappropriate or no longer available. The use of compounded medications has grown in both companion and livestock animal health services to achieve better treatment results while making it easier for animals to take their medications and protect their well-being. The administration of these essential drugs becomes necessary when pets display allergic reactions to inactive components in standard medications, or when weight-based dosing requires individualized measurement, or when pets need flavored medication to improve administration. Pet wellness expenditures continue to rise alongside the global growth of the pet population, leading to increased demand for customized veterinary medications. The expanding complexities of veterinary treatments that involve dermatology, endocrinology, oncology, neurology, and chronic pain management have significantly increased the need for personalized therapeutic solutions. The pet humanization trend and the expansion of the global compounding pharmacy network continue to fuel market growth.

For instance, in September 2024, WEDGEWOOD PHARMACY introduced compounded molnupiravir into its formulary as a new therapy for first- and second-line treatment of Feline Infectious Peritonitis (FIP). The original human medical compound was specially flavored and prepared to make it suitable for cats. WEDGEWOOD PHARMACY stands as the inaugural U.S. veterinary compounding pharmacy to offer cat-friendly molnupiravir formulations, which include different dosage options that address various FIP types, including Effusive, Non-effusive, Neurological, and Ocular. The preparations come in both flavored suspension and capsule forms.

Rising Pet Ownership Trend and Humanization of Pets Boost Market Demand

Pet ownership trends, along with the rising humanization of pets, are the primary forces driving the expansion of the animal drug compounding market. The growing number of pet owners who treat their animals as family members drives a substantial market need for healthcare products that offer personalization. The current pet owner population prioritizes individualized treatment approaches through dose modifications, flavor customization, and diverse administration options, which enhance therapeutic outcomes. The developing emotional connection between people and their pets now requires veterinary care services to match human medical standards. Compounded medications offer adaptable solutions when standard pharmaceutical products fail to meet patient needs or when products become unavailable or discontinued. For example, compounding enables the development of customized liquid medications and topical gels which match the individual characteristics of feline patients and canine patients according to their size, breed and health conditions. Customized pharmaceutical solutions enhance patient comfort and treatment effectiveness while simplifying medication administration for patients with persistent and complex health conditions. The rising number of pets and the demand for tailored treatment solutions have made compounding pharmacies essential in veterinary medical practice. The expanding pet care culture drives market growth, emphasizing the need for individualized pharmaceutical solutions to meet the demands of modern pet owners.

For instance, according to the American Pet Products Association's (APPA) survey report, as of March 2025, 94 million U.S. households now own at least one pet, up from 82 million in 2023. The rising population of pet ownership increases the demand for animal drug compounding to enhance the medication solutions for their pets and provide them with a higher quality of life.

Advancement in Compounding Technology Fuels Market Growth

Advancements in compounding technology significantly fuel the growth of the animal drug compounding market by enhancing the precision of medication preparation while increasing efficiency and safety. The use of automated equipment in modern compounding pharmacies, including precision mixers and capsule fillers, together with electronic balances, leads to improved consistency and accuracy in custom drug formulations. Technology minimizes human errors and ensures accurate dosing, while also enhancing processing speed, making compounded medications more dependable and easier for veterinarians and pet owners to obtain. The pharmaceutical industry has developed new excipients and delivery systems that include transdermal gels, along with flavored suspensions and medicated treats, which now offer multiple administration methods while enhancing palatability for companion animals. Pharmacies optimize their operations and maintain proper safety standards through advanced software solutions, which enable inventory tracking, prescription management, and regulatory compliance. The installation of sterile compounding facilities, along with quality assurance protocols, ensures that veterinary and human health standards are consistently met for all medications. Veterinary professionals show increased confidence in compounded medications due to these technological advancements, which enhance both production speed and quality. Technological advancements drive the global growth of animal drug compounding services while improving their reliability.

For instance, in January 2025, Covetrus Inc. launched a cloud-based compounding prescription platform called the Covetrus Platform, which comprises an integrated solution set designed to meet the needs of contemporary veterinary operations. The Covetrus Platform collaborates with the expanding VetSuite network to deliver comprehensive veterinary clinic capabilities nationwide.

Oral Route of Administration Segment Holds the Largest Market Share

The oral route of administration holds the largest market share in the animal drug compounding market due to its universal approval and species versatility, as well as its user-friendly nature. Veterinarians, along with pet owners, often select flavored liquids, chewable tablets, capsules, and pastes as their preferred oral medications because these options simplify the administration of drugs to companion animals, including dogs and cats. Compounding pharmacies create customized medications that improve taste to increase animal compliance for those animals that resist medication intake. Chronic conditions need this method because it provides ongoing daily medication for arthritis infections and endocrine disorders. The flexibility of oral formulations stems from their ability to customize doses according to weight, species, and individual health requirements, resulting in cost savings. Through oral delivery, pharmacists can access numerous active pharmaceutical ingredients (APIs) to develop individualized treatment options that are more effective than commercial drugs or when commercial products are not available. The advancement of flavor masking techniques, combined with improvements in formulation stability, has enhanced both the performance and storage duration of compounded oral medications. The increasing demand for customized pet medications, together with easy administration techniques, sustains oral administration as the leading method in animal drug compounding markets.

For instance, in October 2023, Evonik Industries AG launched EUDRACAP, a ready-to-use oral capsule filler designed for use in preclinical trials. This technical-grade capsule is suitable for passing through the gastrointestinal tract of preclinical animal models. The company also introduced this on the clinical and commercial stages using the EUDRACAP platform.

North America Dominates Animal Drug Compounding Market Size

North America dominates the animal drug compounding market due to its advanced veterinary healthcare facilities, high pet ownership rates, and supportive regulations. The United States holds a significant portion of the market due to its growing demand for personalized pet medications that cater to specific health conditions, dosage requirements, and species-specific formulations. Veterinary professionals, along with pet owners, turn to compounded medications as their first choice when commercial drugs become unavailable, unsuitable, or discontinued. The regional market receives additional strength from Wedgewood Pharmacy and other leading compounding pharmacies. The regional market is bolstered by Wedgewood Pharmacy and other leading compounding pharmacies, which offer a range of dosage forms, flavors, and delivery methods for both companion animals and livestock. The region maintains established distribution networks, along with professional veterinary associations, which continually invest in veterinary compounding techniques and training. Regulatory bodies such as the U.S. FDA develop operational rules for pharmacies while promoting safety standards for compounded medications. The growing awareness of pet health needs, combined with the rise of chronic disease management and pet humanization trends, is driving market demand for customized medical solutions. The combination of various market elements establishes North America as the primary force in the worldwide animal drug compounding industry.

For instance, in December 2024, Grey Wolf Animal Health Corp., a Toronto-based company, completed the acquisition of Compounding Pharmacy of Manitoba. Grey Wolf enhances its ability to provide custom veterinary drugs through the growth of its pharmacy business unit and expanded capacity to deliver veterinary and human compounding services. Through its acquisition of Trutina and Compounding Pharmacy of Manitoba, Grey Wolf expands its customer base while increasing access to specialized animal medications and driving market growth.

Impact of U.S. Tariffs on Animal Drug Compounding Market

The implementation of U.S. tariffs on pharmaceutical ingredients and raw materials imported from overseas has a significant impact on the animal drug compounding industry. Several compounded medications rely on receiving their active pharmaceutical ingredients (APIs) and excipients from suppliers in China and India. Tariffs increase the expense of imported goods, which raises production costs for veterinary compounding pharmacies. Higher production costs result in elevated prices for compounded medications, which pet owners and veterinary facilities must pay. Smaller veterinary compounding operations encounter difficulties when increasing prices due to their reliance on tight profit margins, which sustain their individualized animal medication offerings. Supply chain restrictions that block access to ingredients lead to medication delays, which in turn postpone necessary medical treatments. The transition toward domestic sourcing by providers results in higher expenses or reduced product availability. The implementation of tariffs generates financial strain on compounding pharmacies while endangering both the affordability and availability of animal medical care.

Key Players Landscape and Outlook

The competitive landscape operates through innovation, acquisitions, and service expansion. Custom formulation delivery, compounding technology, quality assurance, and training investment drive company growth. Strategic partnerships, combined with geographical expansion, enable companies to achieve a broader market reach. Their competitive advantage is strengthened through species-specific solutions and delivery forms that meet compliance requirements and stringent regulatory standards. The market outlook appears positive, as personalized veterinary care shows increasing demand, while R&D investments are expected to continue driving both market growth and product differentiation.

In May 2024, Mixlab, Inc. acquired NexGen Animal Health, enabling the expansion of its advanced compounding pharmacy operations from companion animal services to include extensive animal health services. Mixlab aims to utilize its technology platform to enhance pharmacy services for large animal practitioners and owners, while improving production efficiency and supporting ongoing development.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Animal Drug Compounding Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product
      • 5.2.1.1. Anti-infective Agents
      • 5.2.1.2. Anti-inflammatory Agents
      • 5.2.1.3. Hormones and Substitutes
      • 5.2.1.4. CNS Agents
      • 5.2.1.5. Others
    • 5.2.2. By Animal Type
      • 5.2.2.1. Companion Animals
        • 5.2.2.1.1. Dogs
        • 5.2.2.1.2. Cats
        • 5.2.2.1.3. Horses
        • 5.2.2.1.4. Others
      • 5.2.2.2. Livestock Animals
    • 5.2.3. By Route of Administration
      • 5.2.3.1. Oral
      • 5.2.3.2. Injectable
      • 5.2.3.3. Topical
    • 5.2.4. By Dosage Form
      • 5.2.4.1. Suspensions
      • 5.2.4.2. Solutions
      • 5.2.4.3. Capsules
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia-Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East and Africa
    • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Product
    • 5.3.2. By Animal Type
    • 5.3.3. By Route of Administration
    • 5.3.4. By Dosage Form
    • 5.3.5. By Region

6. North America Animal Drug Compounding Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
      • 6.2.1.1. By Product
        • 6.2.1.1.1. Anti-infective Agents
        • 6.2.1.1.2. Anti-inflammatory Agents
        • 6.2.1.1.3. Hormones and Substitutes
        • 6.2.1.1.4. CNS Agents
        • 6.2.1.1.5. Others
      • 6.2.1.2. By Animal Type
        • 6.2.1.2.1. Companion Animals
          • 6.2.1.2.1.1. Dogs
          • 6.2.1.2.1.2. Cats
          • 6.2.1.2.1.3. Horses
          • 6.2.1.2.1.4. Others
        • 6.2.1.2.2. Livestock Animals
      • 6.2.1.3. By Route of Administration
        • 6.2.1.3.1. Oral
        • 6.2.1.3.2. Injectable
        • 6.2.1.3.3. Topical
      • 6.2.1.4. By Dosage Form
        • 6.2.1.4.1. Suspensions
        • 6.2.1.4.2. Solutions
        • 6.2.1.4.3. Capsules
    • 6.2.2. By Country Share
      • 6.2.2.1. United States
      • 6.2.2.2. Canada
      • 6.2.2.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Animal Drug Compounding Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Product
          • 6.3.1.2.1.1. Anti-infective Agents
          • 6.3.1.2.1.2. Anti-inflammatory Agents
          • 6.3.1.2.1.3. Hormones and Substitutes
          • 6.3.1.2.1.4. CNS Agents
          • 6.3.1.2.1.5. Others
        • 6.3.1.2.2. By Animal Type
          • 6.3.1.2.2.1. Companion Animals
          • 6.3.1.2.2.1.1. Dogs
          • 6.3.1.2.2.1.2. Cats
          • 6.3.1.2.2.1.3. Horses
          • 6.3.1.2.2.1.4. Others
          • 6.3.1.2.2.2. Livestock Animals
        • 6.3.1.2.3. By Route of Administration
          • 6.3.1.2.3.1. Oral
          • 6.3.1.2.3.2. Injectable
          • 6.3.1.2.3.3. Topical
        • 6.3.1.2.4. By Dosage Form
          • 6.3.1.2.4.1. Suspensions
          • 6.3.1.2.4.2. Solutions
          • 6.3.1.2.4.3. Capsules
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Animal Drug Compounding Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Animal Drug Compounding Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Animal Drug Compounding Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Animal Drug Compounding Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

  • 17.1. Technology Overview
  • 17.2. Recent Launches and Approvals

18. Regulatory Framework and Innovation

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Partners Group
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. Vimian Group AB
    • 20.3.3. Akina Animal Health
    • 20.3.4. Davis Islands Pharmacy and Compounding Lab
    • 20.3.5. Custom Med Compounding Pharmacy
    • 20.3.6. Central Compounding Center South
    • 20.3.7. Wellness Pharmacy of Cary
    • 20.3.8. Kubat HealthCare
    • 20.3.9. Medisca Inc.
    • 20.3.10. Chiron Pharmaceuticals Private Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 3. Global Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 4. Global Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 5. Global Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 6. Global Animal Drug Compounding Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 8. North America Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 9. North America Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 10. North America Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 11. North America Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 12. North America Animal Drug Compounding Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 14. United States Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 15. United States Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 16. United States Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 17. United States Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 18. Canada Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Canada Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 20. Canada Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 21. Canada Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 22. Canada Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 23. Mexico Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Mexico Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 25. Mexico Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 26. Mexico Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 27. Mexico Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 28. Europe Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Europe Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 30. Europe Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 31. Europe Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 32. Europe Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 33. Europe Animal Drug Compounding Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Germany Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 36. Germany Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 37. Germany Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 38. Germany Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 39. France Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 40. France Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 41. France Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 42. France Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 43. France Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 44. Italy Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Italy Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 46. Italy Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 47. Italy Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 48. Italy Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 49. United Kingdom Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. United Kingdom Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 51. United Kingdom Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 52. United Kingdom Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 53. United Kingdom Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 54. Russia Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 55. Russia Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 56. Russia Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 57. Russia Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 58. Russia Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 59. Netherlands Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Netherlands Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 61. Netherlands Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 62. Netherlands Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 63. Netherlands Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 64. Spain Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Spain Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 66. Spain Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 67. Spain Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 68. Spain Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 69. Turkey Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Turkey Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 71. Turkey Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 72. Turkey Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 73. Turkey Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 74. Poland Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Poland Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 76. Poland Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 77. Poland Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 78. Poland Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 79. South America Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 80. South America Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 81. South America Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 82. South America Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 83. South America Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 84. South America Animal Drug Compounding Market Share (%), By Country, 2018-2032F
  • Figure 85. Brazil Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. Brazil Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 87. Brazil Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 88. Brazil Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 89. Brazil Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 90. Argentina Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Argentina Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 92. Argentina Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 93. Argentina Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 94. Argentina Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 95. Asia-Pacific Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 96. Asia-Pacific Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 97. Asia-Pacific Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 98. Asia-Pacific Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 99. Asia-Pacific Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 100. Asia-Pacific Animal Drug Compounding Market Share (%), By Country, 2018-2032F
  • Figure 101. India Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. India Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 103. India Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 104. India Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 105. India Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 106. China Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. China Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 108. China Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 109. China Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 110. China Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 111. Japan Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 112. Japan Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 113. Japan Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 114. Japan Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 115. Japan Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 116. Australia Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 117. Australia Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 118. Australia Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 119. Australia Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 120. Australia Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 121. Vietnam Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 122. Vietnam Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 123. Vietnam Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 124. Vietnam Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 125. Vietnam Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 126. South Korea Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 127. South Korea Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 128. South Korea Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 129. South Korea Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 130. South Korea Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 131. Indonesia Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. Indonesia Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 133. Indonesia Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 134. Indonesia Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 135. Indonesia Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 136. Philippines Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 137. Philippines Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 138. Philippines Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 139. Philippines Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 140. Philippines Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 141. Middle East & Africa Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 142. Middle East & Africa Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 143. Middle East & Africa Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 144. Middle East & Africa Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 145. Middle East & Africa Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 146. Middle East & Africa Animal Drug Compounding Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. Saudi Arabia Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 149. Saudi Arabia Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 150. Saudi Arabia Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 151. Saudi Arabia Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 152. UAE Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 153. UAE Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 154. UAE Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 155. UAE Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 156. UAE Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 157. South Africa Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
  • Figure 158. South Africa Animal Drug Compounding Market Share (%), By Product, 2018-2032F
  • Figure 159. South Africa Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
  • Figure 160. South Africa Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
  • Figure 161. South Africa Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
  • Figure 162. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 163. By Animal Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 165. By Dosage Form Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024